Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease
Our study demonstrates that RCC is a significant burden for VHL patients, with high rates of disease progression, surgery, and metastasis development, even in a closely monitored, multidisciplinary clinical environment, and identifies CKD as an underappreciated aspect of VHL. These findings can provide a context for the antitumor activity of new treatments for RCC.
Authors
- Sandeep Gurram (ORCID: https://orcid.org/0000-0002-6405-9269)
- Krista Reynolds
- Alexis Rompré‐Brodeur (ORCID: https://orcid.org/0000-0001-8177-0514)
- Cathy Anne Pinto (ORCID: https://orcid.org/0000-0002-7793-1706)
- W. Marston Linehan
- Mark W. Ball (ORCID: https://orcid.org/0000-0003-1780-2627)
- Julie Fox (ORCID: https://orcid.org/0000-0002-0583-8019)
- Ananya Roy (ORCID: https://orcid.org/0000-0002-0706-3237)
- Cathy D. Vocke (ORCID: https://orcid.org/0000-0002-9256-7607)
- Rafia Bosan (ORCID: https://orcid.org/0000-0003-4226-6715)
- Yanfang Liu (ORCID: https://orcid.org/0009-0004-5562-6569)
- Zoë Blake (ORCID: https://orcid.org/0000-0002-3924-8690)
- Rodolfo F. Perini (ORCID: https://orcid.org/0009-0002-4400-5260)
- Rabindra Gautam
- Deborah Nielsen
- Beth Ryan
- Mengying Li (ORCID: https://orcid.org/0000-0002-4699-5010)
- Kristin Choo
- Peter Pinto
- Ramaprasad Srinivasan
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- IQVIA (United States) (US)
- National Cancer Institute (US)
Publication Details
- Journal
- European Urology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.eururo.2025.03.002
- Citations
- 6
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.11